Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy
2011

Adrenal Suppression: A Guide for Screening and Management

publication Evidence: moderate

Author Information

Author(s): Ahmet Alexandra, Kim Harold, Spier Sheldon

Primary Institution: University of Ottawa, Children's Hospital of Eastern Ontario

Hypothesis

What are the risks and management strategies for adrenal suppression in children using inhaled corticosteroids?

Conclusion

Adrenal suppression is a serious but often unrecognized complication of high-dose inhaled corticosteroid therapy in children, which can lead to significant health issues if not properly managed.

Supporting Evidence

  • Adrenal suppression can persist for up to 1 year after stopping corticosteroid treatment.
  • More than 60 cases of adrenal suppression have been documented in children treated with high doses of fluticasone.
  • Regular follow-up and awareness can minimize the risk of adrenal suppression.

Takeaway

Inhaled corticosteroids can sometimes make it hard for the body to produce a hormone called cortisol, which is important for stress. Doctors need to check for this problem, especially in kids taking high doses.

Methodology

This review summarizes current literature and provides recommendations for screening and managing adrenal suppression in children using inhaled corticosteroids.

Potential Biases

Potential bias may arise from the authors' affiliations and funding sources.

Limitations

The review highlights the lack of national guidelines for screening and the variability in practices among healthcare centers.

Participant Demographics

The article primarily discusses children and adolescents with asthma.

Digital Object Identifier (DOI)

10.1186/1710-1492-7-13

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication